News

GlobeImmune's Gilead-partnered hep B vaccine fails in Phase II

GlobeImmune's in-development vaccine for hepatitis B missed the mark in a Phase II trial, marring the value of a program licensed to Gilead Sciences.

Post-swap Novartis preps cancer drug R&D road show

Two of the cancer drugs Novartis traded for from GSK--Tafinlar and Mekinist--will post combo survival data at ASCO.

Sanofi splurges $245M on Retrophin's speedy-review voucher

Retrophin is selling its recently acquired coupon for a speedy FDA approval to Sanofi for $245 million in cash.

Bluebird widens its CAR-T ambitions with a $130M Five Prime deal

Bluebird bio, already making headlines with its promising gene therapy, is expanding its efforts in immuno-oncology, pairing up with Five Prime Therapeutics to develop cell therapies for cancer.

CAR-T powerhouse Juno allies with gene-editing upstart Editas in $737M deal

One of the leaders of the CAR-T revolution has now aligned itself in an R&D collaboration with one of the top biotechs to emerge in the hot gene editing field. Juno Therapeutics is tying the knot with Editas on three programs, handing over $47 million in an upfront payment and three years of research support along with up to $690 million in milestones.

HIV biotech Calimmune bags $15M to move one-time gene therapy into new trials

After getting started 9 years ago with backing from angel investors, Calimmune just landed a $15 million B round, positioning the biotech to move into the clinic with a gene therapy designed to durably stymie the lethal HIV with one treatment.

The FierceBiotech/Bloomberg Intelligence survey: Are biotech assets overvalued?

It's time for another FierceBiotech survey! And this time, we've partnered with Bloomberg Intelligence to expand our reach into the global ranks of biopharma execs and analysts.

Sanofi buys into NeuroVive's cardio drug in Korea

Sanofi is betting on the promise of NeuroVive Pharmaceutical's top prospect, buying the South Korean rights to the biotech's Phase III cardiovascular drug.

The Gilead effect: PCSK9 rivals Amgen, Sanofi/Regeneron prep for a price war

With the aggressive pharmaceutical benefits manager Express Scripts lying in wait for two new cholesterol blockbuster contenders expected to debut this summer, the highly anticipated price war appears to already be well underway.

Boehringer snags FDA approval for COPD combo drug

Boehringer Ingelheim picked up FDA approval for a next-generation COPD treatment, looking to contend for a share of the fast-crowding market for combination therapies.

Amicus' rare disease drug lines up for a quick EU approval

Amicus Therapeutics has landed on the European regulatory fast track, potentially shortening the review time for its orphan drug as it prepares filings at home and abroad.

Can PureTech and its high-profile board raise $160M in London?

Boston-based PureTech, an investment group which is better known for its high-profile board than its portfolio of upstart life sciences companies, has landed in the U.K. with a plan to raise $160 million on the London stock market.

UPDATED: Suicide stunner prompts Amgen to dump brodalumab, denting AstraZeneca's rep

A month ago, Amgen and AstraZeneca were confidently rolling up data from three highly touted late-stage studies on the psoriasis drug brodalumab for a new drug application that was widely viewed as a shoo-in at the FDA. But late Friday evening, Amgen abruptly said it was pulling out of the long-running collaboration on the high-profile IL-17 program after evaluating the likely commercial impact it would face in light of the suicidal thoughts some patients reported during the studies.

China's Cellular Biomedicine spikes on early CAR-T data

Shanghai drug developer Cellular Biomedicine reported some positive results from a small study of its in-development cancer immunotherapy, sending its shares up more than 15% on Friday.

Chinese drugmakers snag antibody expert Ambrx in joint buyout

A group of Chinese biotech heavyweights are banding together to buy Ambrx, R&D partner to the likes of Bristol-Myers Squibb and Merck, in hopes of making the company a go-to collaborator in their native country.

Ex-Pfizer exec Gutiérrez-Ramos heads to startup Synlogic

Welcome to this week's Chutes and Ladders, our roundup of hirings and retirings throughout the industry. Please send the good word--or the bad--from your shop to Eric Sagonowsky (email) or...

Novartis' duo of COPD drugs clears Phase III on the path to an FDA decision

Novartis, working to get a pair of Europe-approved COPD treatments onto the U.S. market, reported some positive Phase III data while awaiting final word from the FDA.

Amgen's PCSK9 contender lines up for first place in the blockbuster EU race

Amgen is likely to come in second in the race to launch new cholesterol treatments in the U.S., but the Big Biotech is leading the charge in Europe, securing a crucial regulatory recommendation that clears the way for approval.

Otonomy's ear disease drug slips in Phase IIb, but management keeps the faith

Otonomy's treatment for a balance-destroying ear disease missed the mark in a Phase IIb study--but it was close, and the biotech believes the drug did well enough to merit moving forward into late-stage testing.

Abivax files for IPO, Pluristem boards EMA fast-track, Ablynx inks Genzyme MS deal

In this week's EuroBiotech Report, Abivax became the latest French biotech to file for an IPO in its home country, seeking cash ahead of moving an HIV drug into two Phase IIb trials, as well as to support the clinical development of its lead candidate, a therapeutic vaccine against hepatitis B. And more.